ProQR Therapeutics (PRQR) Competitors $1.99 -0.20 (-9.13%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.50%) As of 09/15/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. SYRE, SPRY, PRAX, QURE, ATAI, CRON, CRMD, TSHA, IMNM, and AMLXShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), Cronos Group (CRON), CorMedix (CRMD), Taysha Gene Therapies (TSHA), Immunome (IMNM), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Its Competitors Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure atai Life Sciences Cronos Group CorMedix Taysha Gene Therapies Immunome Amylyx Pharmaceuticals ProQR Therapeutics (NASDAQ:PRQR) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Is PRQR or SYRE more profitable? Spyre Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -238.52%. ProQR Therapeutics' return on equity of -61.25% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-238.52% -61.25% -28.13% Spyre Therapeutics N/A -71.30%-38.69% Which has more volatility and risk, PRQR or SYRE? ProQR Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Do insiders & institutionals have more ownership in PRQR or SYRE? 32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer PRQR or SYRE? ProQR Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 302.01%. Spyre Therapeutics has a consensus price target of $53.40, suggesting a potential upside of 259.84%. Given ProQR Therapeutics' higher probable upside, research analysts plainly believe ProQR Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has higher earnings and valuation, PRQR or SYRE? ProQR Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$20.46M10.23-$30.04M-$0.46-4.33Spyre Therapeutics$890K1,007.12-$208.02M-$3.40-4.36 Does the media favor PRQR or SYRE? In the previous week, Spyre Therapeutics had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 4 mentions for ProQR Therapeutics. Spyre Therapeutics' average media sentiment score of 1.07 beat ProQR Therapeutics' score of 1.03 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryProQR Therapeutics beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.41M$3.15B$5.79B$10.18BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-4.3321.2474.8626.39Price / Sales10.23466.65543.67125.97Price / CashN/A44.4425.8129.91Price / Book2.199.6413.256.28Net Income-$30.04M-$53.20M$3.29B$270.38M7 Day Performance-14.59%0.07%0.07%1.89%1 Month Performance-2.93%4.27%4.60%6.01%1 Year Performance8.74%9.62%72.95%25.26% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.6342 of 5 stars$1.99-9.1%$8.00+302.0%+7.6%$230.41M$20.46M-4.33180News CoveragePositive NewsShort Interest ↑SYRESpyre Therapeutics2.2599 of 5 stars$16.63-2.2%$53.40+221.1%-49.5%$1.03B$890K-4.8973News CoveragePositive NewsSPRYARS Pharmaceuticals2.6005 of 5 stars$10.70+6.3%$32.50+203.7%-25.1%$995.18M$89.15M-21.8490PRAXPraxis Precision Medicines2.4635 of 5 stars$40.75-13.0%$85.88+110.7%-32.4%$985.99M$8.55M-3.32110Gap DownHigh Trading VolumeQUREuniQure3.2082 of 5 stars$17.43-2.9%$37.45+114.9%+162.2%$984.86M$27.12M-4.45500ATAIatai Life Sciences2.876 of 5 stars$4.52-1.1%$11.25+148.9%+257.7%$979.53M$2.31M-6.5580Positive NewsCRONCronos Group2.4881 of 5 stars$2.48-0.8%N/A+17.0%$957.23M$117.61M49.60450CRMDCorMedix3.9112 of 5 stars$12.75+2.8%$17.33+35.9%+82.0%$925.65M$43.47M17.0030Analyst UpgradeInsider TradeTSHATaysha Gene Therapies2.4719 of 5 stars$3.24-3.6%$8.29+155.7%+31.9%$916.59M$8.33M-9.53180Positive NewsInsider TradeIMNMImmunome2.3212 of 5 stars$9.40-10.6%$22.89+143.5%-40.6%$915.71M$9.04M-3.0540Positive NewsAMLXAmylyx Pharmaceuticals2.1984 of 5 stars$10.44+2.4%$12.25+17.3%+352.3%$909.51M$87.37M-4.18200Positive NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies Spyre Therapeutics Competitors ARS Pharmaceuticals Competitors Praxis Precision Medicines Competitors uniQure Competitors atai Life Sciences Competitors Cronos Group Competitors CorMedix Competitors Taysha Gene Therapies Competitors Immunome Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRQR Stock Alerts